Abstract
Post-operative increases in intraocular pressure (IOP) are a frequent complication following phacoemulsification cataract surgery. Assessment of IOP is an essential element in post-operative checks. Despite this, guidance regarding the optimal timing remains vague. The purpose of this meta-analysis was to determine the current status of evidence that may help guide best practice regarding the optimal time following phacoemulsification cataract surgery to measure IOP. A comprehensive literature search was performed on MEDLINE and EMBASE. In two stages, independent reviewers screened articles that reported IOP measurements following uncomplicated cataract surgery. Risk of Bias Assessment was conducted following data extraction. The meta-analysis incorporated 57 randomized clinical studies involving a total of 6318 participants and 7089 eyes. Post-operative hour one had a significant decrease in IOP from baseline, while hour two had a non-significant increase. Post-operative hours four, six, and eight were the only timepoints to have a significant increase in IOP. Finally, post-operative day one had no significant change in IOP, while day two had a non-significant decrease. These results suggest that the optimal time to measure IOP is within the first 4–8 h following phacoemulsification cataract extraction. Taking measurements too soon or too late could result in missed IOP spikes.
1. Introduction
Cataractogenesis is a normal physiological change associated with aging and is the leading cause of reversible visual impairment worldwide, affecting 95 million people globally and 3.5 million Canadians [,]. This incidence is expected to increase as both North America’s and the world’s population continues to age [,]. Through surgical intervention, cataracts can be treated with minimal complications []. Consequently, cataract extraction surgery has become a prevalent procedure and is projected to experience significant growth, both in North America and worldwide [,].
Phacoemulsification is the primary method for cataract removal in developed countries. It offers several advantages, including smaller incisions, less tissue damage, and a lower risk of complications after surgery [,].
A common complication of cataract surgery is elevation of intraocular pressure (IOP). This can occur in both expert and novice hands, largely due to the incomplete aspiration of viscoelastic materials used to facilitate the extraction []. These IOP spikes can result in increased morbidity in the acute period immediately following, and up to one month after, cataract surgery [,]. This includes pain, nausea, vomiting, corneal edema, and blurred vision, which can all result in the patient contacting the operating surgeon or being brought to the emergency room [,,,]. Additionally, in eyes with pre-existing optic nerve damage, such as those with glaucoma or atherosclerosis-related ischemia, IOP spikes can cause worsening of these sight-threatening diseases [].
The American Academy of Ophthalmology (AAO) provided guidelines regarding the optimal timing of IOP measurements post-surgery in the “2021 Cataract in the Adult Eye Preferred Practice Patterns” []. The AAO recommended that IOP should be measured within the first 48 h after surgery in patients with low-risk surgeries and with no signs or symptoms of possible complications following cataract surgery. Additionally, these preferred practice patterns recommend that functionally monocular patients and those at high risk of early postoperative complications should have their IOP measured within the first 24 h after surgery. More specific recommendations regarding the exact timing are not indicated. The timing has thus become more a matter of convenience for the surgeon rather than when the undesired outcome is most likely to be detected. The lack of more specific guidance likely accounts for the variability of IOP measurements noted within the first 48 h post-surgery.
The purpose of this meta-analysis was to review and synthesize the available evidence to determine if there is an optimal period following phacoemulsification cataract surgery to measure IOP. The goal was to help guide surgeons and healthcare systems regarding best practice.
2. Materials and Methods
2.1. Search Strategy
A literature search was conducted in the following two databases: MEDLINE and EMBASE. The search had no limitations placed on publication date and, therefore, included all studies published before 7 February 2023. Sets of keywords relating to Intraocular Pressure, after (i.e., post, following), and Cataract Surgery (i.e., cataract surgery, cataract surgeries) were used with restrictions placed on adult human subjects, English-published literature, and randomized clinical trials. All articles were then imported into Covidence (Veritas Health Innovation, n.d.), which is a web-based systematic review screening tool that was used to remove duplicates and create two levels of screening: title and abstract screening and full-text screening.
After all articles had been imported into Covidence, two reviewers independently screened titles and abstracts for articles that measured IOP following uncomplicated cataract surgery. Articles that were accepted past the first level of screening then proceeded through a second level of screening where three reviewers independently screened full texts for publications that accurately measured IOP following uncomplicated phacoemulsification cataract surgery. Conflicts at both levels of screening were resolved through discussion to find a consensus between the reviewers (WJH, BEY, and HSA). In cases where consensus was not achieved, the third reviewer was used to provide a decision. After each screening level, chance-corrected kappa statistic was used to assess interobserver agreement for the inclusion of studies. This study’s detailed protocol was registered through Inplasy (Registration number: INPLASY202490004).
2.2. Inclusion and Exclusion Criteria
The population of interest consisted of human adults who, following routine cataract surgery, had their intraocular pressure measured. First, included publications were required to report a measurement of IOP through tonometry and after completion of cataract surgery. Second, at least one IOP measurement had to have taken place at three different timepoints: at baseline before cataract surgery, within the first 48 h following cataract surgery, and after these first 48 h. The timeline criteria are in line with 2021 Cataract in the Adult Eye Preferred Practice Patterns []. Third, the IOP measurement outside the first 48 h was used to ensure IOP did decrease relative to baseline after this acute rise. Studies were included if the cataract extraction method of choice was phacoemulsification. Fourth, studies that examined participants who, in addition to cataracts, also had glaucoma and pseudoexfoliation syndrome (PXF) were included. Lastly, only randomized clinical trials published in English were considered for this review.
Studies were excluded if the cataract surgery was combined with another ophthalmologic surgery. Publications that focused on participants younger than 18 or had an ophthalmologic condition other than cataract or glaucoma were excluded. Exclusion criteria were nonhuman and non-English studies. Studies that reported IOP data in figure form that could not be accurately determined were also excluded. No limits were placed on study location, publication date, or sex.
2.3. Risk of Bias Assessment
The quality of each study was assessed using the CLARITY risk of bias instrument for randomized controlled trials []. This assessment tool measures the risk of bias based on six factors: (1) adequacy of allocation sequence generation, (2) adequacy of allocation concealment, (3) study blinding, which is further subdivided into 3a. patient blinding, 3b. healthcare provider blinding, 3c. data collectors blinding, 3d. outcome assessors blinding, 3e. data analysts blinding, (4) frequency of missing outcome data lost during follow-up, (5) degree of selective outcome reporting, and (6) Other potential problems that could put the study at risk of bias. For missing data, various pieces of available information (such as the range, p-value, and confidence interval) were utilized and converted to the common effect measure.
2.4. Data Extraction
For each included study, quantitative and qualitative information related to participants’ IOP was collected independently. The following data were extracted: study information (i.e., author and year), study characteristics (i.e., number of participants, number of eyes examined, mean age of participants, sex of participants, location of study, disease population of interest, study blinding, and corporate funding), study surgical parameters (i.e., Ophthalmic Viscosurgical Device (OVD) used, method of phacoemulsification, and pre-operative, intra-operative, and postoperative medications used), and studies IOP specific characteristics (i.e., time of IOP measurement, pre-operative baseline IOP measurement, all IOP measurements within the first 48 h post-cataract surgery, one IOP measurement outside these first 48 h, method of IOP measurement, patient’s position during IOP measurement, and any IOP measurement corrections related to clear corneal thickness measurements). Data entry was extracted manually from studies into an Excel sheet. Further, corresponding authors were also contacted for additional information.
2.5. Statistical Analysis
Meta-analysis was completed using STATA v. 18.0 (STATA Corporation, 2023, College Station, TX, USA). The main outcomes of interest were the mean and standard deviation (SD) of pre- and post-operative IOP. For change in IOP, the standardized mean difference (SMD) was calculated as the mean difference in IOP from baseline. To test heterogeneity, statistics, Z-value, and χ2 statistics were computed. A value of less than 50% implied low heterogeneity, and, in these cases, a fixed-effect model was computed. Statistics of 50% or more represented high heterogeneity, and, in these cases, a random-effect model was calculated. Additionally, a high Z-value, a low p-value (<0.01), and a large value implied significant heterogeneity, and, therefore, a random-effect model using DerSimonian and Laird methods was computed. This study adopted a significance level of 0.05. Forest plots were also generated for each case. Funnel plots were generated to check publication bias. If funnel plots were found to be asymmetrical, standard Egger’s regression test for small-study effects and the Trim and Fill method were performed to further check for publication bias. Causes of heterogeneity were also explored.
3. Results
3.1. Search Results
Database searches resulted in 855 published literature records. The 855 records were then imported into the Covidence systematic review software, version 2.0, with 230 duplicates being removed. At the end of the title and abstract screening, 237 articles remained that moved on to the full-text screening. After the full-text screening, 57 randomized clinical trial studies were included. The Kappa statistic for the first and second levels of screening came to 0.439 and 0.710, respectively. The meta-analysis study retrieval process is detailed in a Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram (Figure 1) [].
Figure 1.
PRISMA flow diagram for optimal timing for intraocular pressure measurement following phacoemulsification cataract surgery.
3.2. Study Characteristics
This meta-analysis included 57 randomized clinical trial studies with a total of 6318 participants and 7089 eyes (Appendix A Table A1) [,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,]. A total of 43.7% of the included participants were male, and the mean age of included participants was 68.4 years old. Four studies did not report the number of male participants. Two studies did not report the mean age of participants. Out of all the studies, 12 were performed in Austria, nine in Turkey, five in Germany, four in the United States, two in Brazil, two in Canada, two in China, two in India, two in Italy, two in Japan, two in Netherlands, one in Czech Republic, one in Finland, one in France, one in Greece, one in Iran, one in Israel, one in Korea, one in Pakistan, one in Poland, one in Spain, one in Sweden, and one in Thailand. In addition, there was one multicentre study in a combination of European countries and one multicentre study across Canada, the United States, Germany, Italy, Mexico, the Philippines, Poland, Spain, and the United Kingdom. Studies’ publication dates ranged from 1992 to 2023, with 65.5% of studies taking place in the last 20 years. A total of 52 studies included patients with only cataracts, two studies looked at cataract patients with glaucoma [,], one study looked at cataract patients with pseudoexfoliation syndrome (PEX) [], one study looked at both patients with only cataract and cataract with PEX [], and one study looked at patients with only cataract, cataract with glaucoma, and cataract with PEX [].
3.3. Risk of Bias Assessment Results
Out of the 57 included studies, 10 were considered at a high risk of bias [,,,,,,,], 21 were considered to have some concerns of bias, and 26 were considered at low risk of bias (Appendix A Table A2). The concerns stemmed from blinding, as 7 studies were open-label, and 3 studies were single-blinded, while 15 studies had unclear information surrounding blinding. Another cause for concern was unclear information about allocation sequence generation and concealment in 31 studies.
3.4. Publication Bias
To assess the risk of publication bias, a funnel plot was generated for every hour IOP was measured following cataract surgery. Figure 2 shows the funnel plot for studies that provided data on the change in IOP for hours 1, 2, 4, 6, and 8, as well as day 1 following phacoemulsification. Included studies for post-operative hours 1, 2, 4, and 8 are scattered symmetrically on either side of the funnel plot; however, there were only a few data points. The funnel plot was symmetrical, but no conclusions could be made due to a smaller sample of studies that took IOP measurements at these timepoints. The funnel plot for post-operative hour 6 had many studies scattered symmetrically along the top of the plot, with fewer along the middle and bottom portions, indicating there were fewer small-scale studies included. The included studies for post-operative day 1 were scattered symmetrically on either side of the plot, although some fell outside the 95% confidence interval. Although the funnel plot at this timepoint appeared symmetrical, it is important to note that this was only one indicator of publication bias.
Figure 2.
(a) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 1 h following phacoemulsification; (b) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 2 h following phacoemulsification; (c) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 4 h following phacoemulsification; (d) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 6 h following phacoemulsification; (e) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 8 h following phacoemulsification; (f) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 1-day following phacoemulsification.
Figure 3 shows the funnel plots for studies that provided data on the change in IOP for days 2, 3, 7, and 30 following phacoemulsification. Included studies for post-operative day 2 were scattered symmetrically on either side of the funnel plot; however, there were only a few data points. The funnel plot appeared to be symmetrical. The funnel plot for post-operative days 3 and 30 had studies scattered slightly asymmetrically, with fewer studies in the bottom left of the plot. Included studies for post-operative day 7 were scattered asymmetrically, with studies missing from the bottom left portion of the plot. As such, this asymmetry implied publication bias at this timepoint. Other potential reasons for asymmetry include difficulty in the interpretation of the funnel plot for a small group of studies, high heterogeneity, and small effect size.
Figure 3.
(a) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 2-days following phacoemulsification; (b) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 3-days following phacoemulsification; (c) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 7-days following phacoemulsification; (d) funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 30-days following phacoemulsification.
Egger’s regression test and trim and fill procedures were performed to further explore potential publication bias for the funnel plots, which appeared asymmetrical at post-operative hours 1, 4, and 8. Funnel plots for hours 1, 4, and 8 include the fitted regression line from the standard Egger’s regression test for small-study effects (Figure 4). However, Egger’s regression test provided weak evidence for the presence of small-study effects. The non-parametric Trim and Fill method of accounting for publication bias in meta-analysis was utilized (Figure 5). For post-operative hours 1, 4, and 8, no “missing” studies were added to the dataset, and, therefore, the variance between studies and evidence of heterogeneity remained unchanged (p = 0.0). Therefore, correction for publication bias does not change the overall interpretation of the dataset.
Figure 4.
(a) Egger’s regression test for included meta-analysis studies that provided data on the change in IOP from baseline at 1 h following phacoemulsification; (b) Egger’s regression test for included meta-analysis studies that provided data on the change in IOP from baseline at 4 h following phacoemulsification; (c) Egger’s regression test for included meta-analysis studies that provided data on the change in IOP from baseline at 8 h following phacoemulsification.
Figure 5.
(a) Non-parametric Trim and Fill method for included meta-analysis studies that provided data on the change in IOP from baseline at 1 h following phacoemulsification; (b) non-parametric Trim and Fill method for included meta-analysis studies that provided data on the change in IOP from baseline at 4 h following phacoemulsification; (c) non-parametric Trim and Fill method for included meta-analysis studies that provided data on the change in IOP from baseline at 8 h following phacoemulsification.
3.5. Effect on IOP
A meta-analysis was performed to evaluate the impact of phacoemulsification cataract extraction on IOP in Figure 6 for follow-up at hours 1, 2, 4, 6, and 8, Figure 7 for 1-day follow-up, and Figure 8 for 2-days, 3-days, 7-days, and 30-days follow-up. Significant heterogeneity was found between studies at the 1 h, 2 h, 4 h, 6 h, 1-day, 2-day, and 3-day follow-up periods (I2 = 83.7%, 98.3%, 55.6%, 77.1%, 88.4%, 52.2%, and 66.7% respectively). Thus, a random-effects meta-analysis was performed for these follow-up timepoints using the DerSimonian and Laird method, given the significant heterogeneity among included articles. A few possible explanations for this significant heterogeneity include different study populations, demographics, study location, technique, surgeon’s experience, available facilities to perform surgery, and rates of complications.
Figure 6.
(a) Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 1 h following phacoemulsification [,]; (b) Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 2 h following phacoemulsification [,,]; (c) Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 4 h following phacoemulsification [,,,]; (d) Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 6 h following phacoemulsification [,,,,,,,,,,,,,,,,]; (e) Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 8 h following phacoemulsification [,,,,].
Figure 7.
Forest plot for included meta-analysis studies that provided data on the change in IOP from baseline at 1-day following phacoemulsification [,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,].
Figure 8.
(a) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 2-days following phacoemulsification [,,]; (b) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 3-days following phacoemulsification [,,,,,,,,,,,]; (c) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 7-days following phacoemulsification [,,,,,,,,,,,,,,,,,,,,,,,,,,,]; (d) Funnel plot for included meta-analysis studies that provided data on the change in IOP from baseline at 30-days following phacoemulsification [,,,,,].
At 1 h follow-up, the results indicated a significant decrease in IOP from baseline (SMD = −2.08 [95% CI: −3.28 to −0.88]). At 2 h follow-up, the results indicated a non-significant increase in IOP (SMD = +0.81 [95% CI: −1.46 to +3.07]). The results indicated a significant increase in IOP at 4-h follow-up (SMD = +1.38 [95% CI: +0.91 to +1.85]), 6 h follow-up (SMD = +0.83 [95% CI: +0.62 to +1.05]), and 8 h follow-up (SMD = +0.93 [95% CI: +0.56 to +1.30]). At 1-day follow-up, the results indicated there was no change in IOP from baseline (SMD = 0.00 [95% CI: −0.17 to +0.17]). At 2-days follow-up, the results indicated a non-significant decrease in IOP from baseline (SMD = −0.36 [95% CI: −0.76 to +0.04]). The results indicated a significant in IOP from baseline at 3-days follow-up (SMD = −0.51 [95% CI: −0.73 to −0.30]), 7-days follow-up (SMD = −0.66 [95% CI: −0.93 to −0.38]), and 30-days follow-up (SMD = −0.60 [95% CI: −0.89 to −0.30]). Therefore, the results indicated significant decreases in IOP from baseline at 1 h, 3-days, 7-days, and 30-days follow-up (Figure 9). Additionally, there were significant increases in IOP at 4 h, 6 h, and 8 h follow-up. Finally, there was a non-significant increase in IOP at 2 h, no change in IOP at 1-day, and a non-significant decrease in IOP at 2-days follow-up.
Figure 9.
Comparative effect size for the change in IOP from baseline at various timepoints following phacoemulsification.
3.6. Surgical Parameters
Out of the 57 studies included in this meta-analysis, all made use of an OVD in their cataract surgery procedure except for one study [], which, instead of an OVD, used a balanced salt solution drip for one of its patient samples (Appendix A Table A3). A total of 17 studies used 1.0% Sodium Hyaluronate, 12 used 4.0% Chondroitin sulphate-3.0% sodium hyaluronate, 11 used 1.4% Sodium Hyaluronate, eight studies used 2.0% Hydroxypropyl Methylcellulose, five used 2.3% Sodium Hyaluronate, three studies used 1.2% Sodium Hyaluronate, and two studies used 1.8% Sodium Hyaluronate. Additionally, only one study used each of the following OVDs: 1.5% Sodium Hyaluronate, 1.6% Sodium Hyaluronate, 3.0% Sodium Hyaluronate, 4.0% Chondroitin sulphate-1.65% sodium hyaluronate, 0.1% chitosan, or 2.2% Sodium hyaluronate—1.0% Sodium hyaluronate. Two studies used sodium hyaluronate with an unknown concentration, one study used chondroitin sulfate–sodium hyaluronate with an unknown concentration, and 15 studies did not report which OVD was used. Additionally, all studies included inserting an intraocular lens during the cataract extraction.
Table A3 found in Appendix A describes the different phacoemulsification techniques used in each study as described by the respective authors. A total of 28 studies reported initial incision size, which ranged from 2.2 to 6.0 mm. Of the 20 studies that reported incision location, 14 used a temporal-placed incision as opposed to the six that used a superior-located incision. Additionally, of the 22 studies that reported incision placement, 17 used a clear corneal while only three used a corneoscleral incision, and two used a limbal incision. A total of 10 studies reported capsulorrhexis size, which ranged from 4.0 to 6.0 mm. A total of 12 studies reported their procedure to follow what was deemed as a traditional or standard phacoemulsification technique. Four studies did not report the surgical technique that was performed.
In terms of the method used to measure IOP in each study, 44 studies reported using Goldmann Applanation Tonometry, four used Non-Contact Tonometry, one used Pneumotonometry, and eight did not report which method was used (Appendix A Table A3). A total of 13 studies measured clear corneal thickness (CCT) through pachymetry, while 44 studies did not (Appendix A Table A3). Out of those studies that did measure CCT, none found a statistically significant difference, and only one study [] corrected for the effect CCT had on IOP measurements. No studies reported correcting IOP based on astigmatism. Out of the 57 studies included in the meta-analysis, only one publication [] reported the exact time of day when IOP was measured, which recorded baseline IOP between 8 a.m. and 4 p.m. No studies reported on the patient’s position during IOP measurement.
3.7. Medications Administered
Out of the 57 included studies, 3 did not report which medications were used in their protocol (Appendix A Table A4). In terms of pre-operative medications, 12 studies administered a non-steroidal anti-inflammatory (NSAID) and, out of those, 11 were diclofenac and one was ketorolac. Five studies administered an antibiotic, with four being a fluoroquinolone and one being an aminoglycoside antibiotic. Additionally, one study administered acetazolamide, one an unspecified anti-glaucoma medication, one an unspecified antibiotic eye drops, and 31 studies reported administering no post-operative medications. Regarding intra-operative medications, five studies administered an antibiotic, with three being a fluoroquinolone, one being a cephalosporin, and one being an aminoglycoside antibiotic. Additionally, five studies administered carbachol, four administered triamcinolone acetonide, one study gave trypan blue, one administered epinephrine, and one gave a fixed dorzolamide–timolol combination. A total of 38 studies did not report medications intraoperatively. Finally, for post-operative medications, 35 studies administered an antibiotic, of which 14 were aminoglycoside, eight fluoroquinolone, five amphenicol, two quinolone, one polypeptide, and one fusidane, and four were unspecified. A total of 27 studies administered a corticosteroid, of those 16 were dexamethasone, six betamethasone, two loteprednol, two triamcinolone acetonide, and one was difluprednate. A total of 20 studies administered a glucocorticoid, of those 18 were prednisolone acetate, one rimexolone, and one was fluorometholone. Additionally, four studies administered an unspecified steroid. A total of 15 studies administered an NSAID, of which 10 used diclofenac, four used ketorolac, and one used indomethacin. Three studies used a dorzolamide–timolol fixed combo, three gave brimonidine, two acetazolamide, two timolol, one dorzolamide, one latanoprost, one brinzolamide, one apraclonidine, one gave an unspecified topical beta-blocker, one study gave an unspecified glaucoma medication, and one study administered both a low-viscosity and high-viscosity tear replacement. Finally, one study administered physostigmine, one gave carbachol, and five studies did not give any post-operative medications.
4. Discussion
A systematic review and a meta-analysis were conducted to determine the current status of evidence that may help guide best practice on the optimal time following phacoemulsification cataract surgery to measure post-operative IOP. Various database searches of randomized clinical trial studies were conducted to measure the change in post-operative IOP compared to pre-operative baseline measurements. The use of OVD, the surgical procedure employed during cataract extraction, and the medications administered were also recorded and analyzed.
The findings from the included articles consistently showed a significant drop in IOP at the 1 h follow-up timepoint. While IOP rose slightly but non-significantly at 2 h, it subsequently increased significantly at 4, 6, and 8 h, reaching its peak elevation during this period. At the 1-day follow-up, IOP returned to baseline levels and then declined non-significantly at the 2-days timepoint. A significant decrease in IOP from baseline was observed for the follow-up timepoints of 3-days, 7-days, and 30-days, marking the first measurements outside the initial 48 h postoperative window. The majority of studies measured IOP using the gold standard of Goldmann Applanation Tonometry [].
These results identified 4 to 8 h following surgery as the optimal time to identify a post-operative IOP spike. The findings also suggested that measuring the IOP sooner than 2 h may be misleading as IOPs were found to be lower than baseline, likely related to surgical techniques to manage wound closure following aspiration of OVD. The results indicated that a continuous decrease in IOP at the 3-days, 7-days, and 30-days is expected and consistent with evidence that retained OVD is unlikely to be causative after 2–3 days []. This would suggest that other causes, such as steroid response, would be a more likely consideration, especially at the 30-day mark [].
The results also demonstrated the significant variability in peri-operative medications used at the time of cataract surgery. A total of 54 studies reported the medications administered at pre-operative, intra-operative, and post-operative stages (Appendix A Table A4). The most common pre-operative medications were either an antibiotic or an NSAID. Intra-operatively, the majority of studies did not report the administration of any medications, but, for those that did, the most common medication given was either an antibiotic, carbachol, and/or a steroid. Post-operatively, the majority of studies used a combination of either an antibiotic, steroid, and/or NSAID. These medication combinations have been shown in some studies to have a small effect on IOP in the immediate days following cataract surgery []. Ten studies reported the use of an IOP-lowering medication, which included carbonic anhydrase inhibitors, beta-blockers, prostaglandin analogs, and alpha agonists []. These medications were used either prophylactically to prevent IOP elevations, to lower IOP in patients who were actively experiencing a dangerous spike, or as routine treatment for glaucoma patients. Despite these medications having peak effects between 2 and 8 h post-administration, they did not seem to prevent the IOP spikes noted from 4 to 8 h later [].
Six of the studies included patients with a known diagnosis of glaucoma or pseudoexfoliation. Only one study measured IOP at the 4 h and 8 h follow-ups, at which time they noted a significant elevation in IOP from baseline at both timepoints []. Additionally, all six publications measured IOP at the 1-day follow-up, at which three saw a slight elevation in IOP while three saw a slight decrease in IOP. These results suggested that perhaps further studies should be performed to more fully understand the risk of IOP spikes in patients with glaucoma and pseudoexfoliation undergoing standalone cataract surgery.
The following limitations should be considered in understanding the context of the results. First, there was some variability in the quality scoring of the included studies. This can be seen in the risk of bias assessment, as a few studies provided unclear information surrounding blinding (Appendix A Table A2). However, as the current literature only offered a small number of relevant publications, all were included, irrespective of their quality score. A second limitation was the asymmetry of a few funnel plots at various post-operative follow-up timepoints. However, after further investigation, Egger’s regression test provided weak evidence for the presence of small-study effects. Additionally, the non-parametric Trim and Fill method indicated correction for publication bias did not change the overall interpretation of the dataset. Therefore, the asymmetry of the funnel plots was most likely not due to publication bias. Asymmetry could have been caused by several other reasons, including difficulty in the interpretation of the funnel plot for a small group of studies, high heterogeneity, and small effect sizes. A third limitation was that only one study corrected for the effect CCT values had on IOP measurements, and no studies corrected for the effect potential astigmatism had on IOP measurements. Additionally, no studies reported patient position during IOP measurement. This is important to note as CCT, astigmatism, and patient position can potentially affect IOP measurements [,]. Finally, there was significant heterogeneity at all post-operative timepoints except for 8 h following phacoemulsification cataract surgery. A few possible explanations for this include different study populations, demographics, study location, technique, surgeon’s experience, available facilities to perform surgery, and rates of complications.
5. Conclusions
Existing relevant studies consistently indicated a noticeable rise in IOP from baseline 4, 6, and 8 h following phacoemulsification cataract surgery. If measurements were made sooner, they risked missing these spikes, which could result in both acute and longer-term negative patient outcomes []. Patients’ perceptions of outcomes and expectations are increasingly becoming considered an important element in healthcare decision-making []. Advancements in cataract surgery have elevated patient expectations in terms of how quickly they achieve an improved visual acuity as well as their overall surgical experience. Continuous practice assessment to determine factors that optimize patient-reported outcomes and experiences in the context of evidence-based quality care may be the key to best practice recommendations.
Author Contributions
Conceptualization, W.J.H., B.E.Y., M.S.M.-M. and C.M.L.H.; methodology, W.J.H., B.E.Y., M.S.M.-M. and C.M.L.H.; validation, W.J.H., B.E.Y. and H.S.A.; formal analysis, W.J.H., B.E.Y., H.S.A. and M.S.M.-M.; data curation, W.J.H., B.E.Y., H.S.A. and M.S.M.-M.; writing—original draft preparation, W.J.H., B.E.Y., M.S.M.-M. and C.M.L.H.; writing—review and editing, W.J.H., B.E.Y., H.S.A., M.S.M.-M. and C.M.L.H.; visualization, W.J.H. and M.S.M.-M.; supervision, M.S.M.-M. and C.M.L.H.; project administration, M.S.M.-M. and C.M.L.H. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors.
Conflicts of Interest
The authors declare no conflicts of interest.
Appendix A
Table A1.
Study characteristics of included studies.
Table A1.
Study characteristics of included studies.
| Author | Year | Study Design | Study Location | Total Number of Participants, N | Total Number of Eyes, N | Age, Mean (SD); Range; N (%), etc. | Male Eyes, N (%) | Disease Population of Interest |
|---|---|---|---|---|---|---|---|---|
| Akbari et al. [] | 2021 | Randomized Clinical Trial | Iran | 88 | 88 | 71.6 (7.8) | 41 (46.6) | Cataract with PEX |
| Akmaz et al. [] | 2023 | Randomized Clinical Trial | Turkey | 65 | 65 | 66.6 (8.8) | 34 (52.3) | Cataract only |
| Arshinoff et al. [] | 2002 | Randomized Clinical Trial | Canada | 99 | 198 | 71.7 (8.6) | 96 (48.5) | Cataract only |
| Asano et al. [] | 2008 | Randomized Clinical Trial | Japan | 142 | 142 | 66.2 (5.5) | 63 (44.4) | Cataract only |
| Auffarth et al. [] | 2017 | Randomized Clinical Trial | Multicenter (Europe) | 220 | 220 | 72.2 (7.6) | 84 (38.2) | Cataract only |
| Balsak et al. [] | 2018 | Randomized Clinical Trial | Turkey | 257 | 277 | 65.9 (13.9) | 142 (51.2) | Cataract only |
| Borazan et al. [] | 2007 | Randomized Clinical Trial | Turkey | 185 | 185 | 67.1 (8.3) | 107 (57.8) | Cataract only |
| Camesaca et al. [] | 2007 | Randomized Clinical Trial | Italy | 143 | 286 | 73.7 (8.9) | 53 (18.5) | Cataract only |
| Cekic et al. [] | 1999 | Randomized Clinical Trial | Turkey | 51 | 51 | 55.7 (-) | 30 (58.8) | Cataract only |
| Cekic et al. [] | 1999 | Randomized Clinical Trial | Turkey | 58 | 58 | 57.3 (31–78) | 35 (60.3) | Cataract only |
| Chang et al. [] | 2017 | Randomized Clinical Trial | Sweden | 43 | 43 | 69.5 (8.3) | - | Cataract only |
| Dieleman et al. [] | 2011 | Randomized Clinical Trial | Netherlands | 400 | 400 | 70.8 (41–91) | 158 (39.5) | Cataract only |
| Dieleman et al. [] | 2012 | Randomized Clinical Trial | Netherlands | 400 | 400 | 70.8 (41–93) | 158 (39.5) | Cataract only |
| el-Harazi et al. [] | 1998 | Randomized Clinical Trial | United States | 58 | 58 | 69.8 (11.0) | 30 (51.7) | Cataract only |
| Fernandez-Barrientos et al. [] | 2010 | Randomized Clinical Trial | Spain | 16 | 16 | 76.7 (5.8) | 9 (56.3) | Cataract with Glaucoma |
| Gungor et al. [] | 2014 | Randomized Clinical Trial | Turkey | 60 | 60 | 70.4 (9.9) | 24 (40.0) | Cataract only |
| Haripriya et al. [] | 2019 | Randomized Clinical Trial | India | 1406 | 1406 | 61.3 (7.4) | 717 (51.0) | Cataract only and, Cataract with PEX |
| Holzer et al. [] | 2001 | Randomized Clinical Trial | United States | 81 | 81 | 71.2 (7.6) | - | Cataract only |
| Holzer et al. [] | 2002 | Randomized Clinical Trial | Germany | 60 | 60 | 67.9 (p = 0.62) | 21 (35.0) | Cataract only |
| Honda et al. [] | 2004 | Randomized Clinical Trial | Japan | 44 | 44 | 61.0 (9.5) | 23 (52.3) | Cataract only |
| Karalezli et al. [] | 2008 | Randomized Clinical Trial | Turkey | 60 | 60 | 66.0 (7.1) | 27 (45) | Cataract only |
| Karalezli et al. [] | 2010 | Randomized Clinical Trial | Turkey | 120 | 120 | 66.6 (8.7) | 68 (56.7) | Cataract only |
| Kim et al. [] | 1996 | Randomized Clinical Trial | Korea | 24 | 24 | 63.0 (5.5) | 9 (37.5) | Cataract only |
| Kohnen et al. [] | 1996 | Randomized Clinical Trial | Germany | 60 | 60 | 73.2 (9.1) | - | Cataract only |
| Kozera et al. [] | 2020 | Randomized Clinical Trial | Poland | 36 | 36 | 71.8 (6.7) | 8 (22.2) | Cataract with Glaucoma |
| Levkovitch-Verbin et al. [] | 2008 | Randomized Clinical Trial | Israel | 122 | 122 | 75.0 (3.8) | 53 (43.4) | Cataract only, Cataract with Glaucoma, and Cataract with PEX |
| Li et al. [] | 2008 | Randomized Clinical Trial | China | 140 | 140 | 72.4 (9.5) | 63 (45.0) | Cataract only |
| Mahajan et al. [] | 2021 | Randomized Clinical Trial | India | 150 | 150 | 64.4 (9.4) | 72 (48.0) | Cataract only |
| Malecaze et al. [] | 2000 | Randomized Clinical Trial | France | 50 | 50 | 75.0 (70–79) | 21 (42.0) | Cataract only |
| Mastropasqua et al. [] | 1998 | Randomized Clinical Trial | Italy | 100 | 100 | 68.2 (11.9) | 55 (55.0) | Cataract only |
| Paganelli et al. [] | 2004 | Randomized Clinical Trial | Brazil | 100 | 100 | 65.2 (7.9) | 48 (48.0) | Cataract only |
| Paganelli et al. [] | 2009 | Randomized Clinical Trial | Brazil | 135 | 135 | 69.2 (8.0) | 54 (40.0) | Cataract only |
| Probst et al. [] | 1993 | Randomized Clinical Trial | Canada | 49 | 50 | 67.6 (12.4) | 28 (56.0) | Cataract only |
| Rabsilber et al. [] | 2007 | Randomized Clinical Trial | Germany | 17 | 34 | 70.1 (9.7) | 12 (35.3) | Cataract only |
| Rainer et al. [] | 2000 | Randomized Clinical Trial | Austria | 25 | 50 | 75.7 (10.5) | 20 (40.0) | Cataract only |
| Rainer et al. [] | 2000 | Randomized Clinical Trial | Austria | 35 | 70 | 75.5 (9.1) | 28 (40.0) | Cataract only |
| Rainer et al. [] | 2001 | Randomized Clinical Trial | Austria | 40 | 80 | 75.9 (9.3) | 26 (32.5) | Cataract only |
| Rainer et al. [] | 2001 | Randomized Clinical Trial | Austria | 40 | 80 | 69.9 (12.1) | 30 (37.5) | Cataract only |
| Rainer et al. [] | 2001 | Randomized Clinical Trial | Austria | 30 | 60 | 64.8 (15.2) | 12 (20) | Cataract only |
| Rainer et al. [] | 2003 | Randomized Clinical Trial | Austria | 38 | 76 | 75.6 (10.9) | 10 (13.2) | Cataract only |
| Saari et al. [] | 2006 | Randomized Clinical Trial | Finland | 20 | 20 | 72.0 (6.3) | 8 (40.0) | Cataract only |
| Sandoval et al. [] | 2006 | Randomized Clinical Trial | United States | 40 | 40 | 71.5 (8.4) | 18 (45.0) | Cataract only |
| Schwenn et al. [] | 2000 | Randomized Clinical Trial | Germany | 48 | 48 | - | - | Cataract only |
| Schwenn et al. [] | 2001 | Randomized Clinical Trial | Germany | 100 | 100 | 71.2 (12.9) | 66 (66.0) | Cataract only |
| Simaroj et al. [] | 2011 | Randomized Clinical Trial | Thailand | 60 | 60 | 66.1 (8.1) | 24 (40.0) | Cataract only |
| Sipos et al. [] | 2011 | Randomized Clinical Trial | Austria | 30 | 60 | 75.2 (8.3) | 22 (36.7) | Cataract only |
| Solomon et al. [] | 1998 | Randomized Clinical Trial | United States | 41 | 41 | 66.9 (11.5) | 26 (63.4) | Cataract only |
| Stifter et al. [] | 2007 | Randomized Clinical Trial | Austria | 50 | 100 | 77.0 (8.4) | 38 (38.0) | Cataract only |
| Stifter et al. [] | 2010 | Randomized Clinical Trial | Austria | 30 | 60 | 79.9 (6.2) | 26 (43.0) | Cataract only |
| Studeny et al. [] | 2014 | Randomized Clinical Trial | Czech Republic | 96 | 192 | 70.2 (8.3) | 70 (36.5) | Cataract only |
| Waseem et al. [] | 2007 | Randomized Clinical Trial | Pakistan | 91 | 91 | - | 51 (56.0) | Cataract only |
| Wedrich et al. [] | 1992 | Randomized Clinical Trial | Austria | 90 | 90 | 76.5 (7.2) | 11 (12.2) | Cataract only |
| Wirtitsch et al. [] | 2007 | Randomized Clinical Trial | Austria | 44 | 88 | 76.0 (8.5) | 22 (25.0) | Cataract only |
| Wu et al. [] | 2018 | Randomized Clinical Trial | China | 81 | 99 | 70.0 (10.0) | 21 (21.2) | Cataract only |
| Yaylali et al. [] | 2004 | Randomized Clinical Trial | Turkey | 48 | 48 | 61.9 (12.2) | 26 (54.2) | Cataract only |
| Zebardast et al. [] | 2020 | Randomized Clinical Trial | Multicentre (Canada, USA, Germany, Italy, Mexico, Philippines, Poland, Spain, UK) | 187 | 187 | 71.2 (7.6) | 82 (43.8) | Cataract with Glaucoma |
| Ziakas et al. [] | 2009 | Randomized Clinical Trial | Greece | 15 | 30 | 72.6 (5.7) | 16 (53.3) | Cataract only |
Table A2.
Results of risk of bias assessment for studies included.
Table A2.
Results of risk of bias assessment for studies included.
| First Author | Year | 1. Was the Allocation Sequence Adequately Generated? | 2. Was the Allocation Adequately Concealed? | 3a. Were Patients Blinded? | 3b. Were Healthcare Providers Blinded? | 3c. Were Data Collectors Blinded? | 3d. Were Outcome Assessors Blinded? | 3e. Were Data Analysts Blinded? | 4. Was Loss to Follow-Up (Missing Outcome Data) Infrequent? | 5. Are Reports of the Study Free of Selective Outcome Reporting? | 6. Was the Study Apparently Free of Other Problems That Could Put It at a Risk of Bias? |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Akbari et al. [] | 2021 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Akmaz et al. [] | 2023 | Definitely yes (low risk of bias) | Probably no | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Arshinoff et al. [] | 2002 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Asano et al. [] | 2008 | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Auffarth et al. [] | 2017 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Balsak et al. [] | 2018 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Borazan et al. [] | 2007 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Probably yes |
| Camesaca et al. [] | 2007 | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably yes | Definitely yes (low risk of bias) | Probably yes |
| Cekic et al. [] | 1999 | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Probably yes | Probably yes |
| Cekic et al. [] | 1999 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Probably yes | Definitely yes (low risk of bias) | Probably yes |
| Chang et al. [] | 2017 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) |
| Dieleman et al. [] | 2011 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Dieleman et al. [] | 2012 | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) |
| el-Harazi et al. [] | 1998 | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Fernandez-Barrientos et al. [] | 2010 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Gungor et al. [] | 2014 | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Haripriya et al. [] | 2019 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Holzer et al. [] | 2001 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Holzer et al. [] | 2002 | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Honda et al. [] | 2004 | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Karalezli et al. [] | 2008 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Probably yes | Probably yes |
| Karalezli et al. [] | 2010 | Definitely yes (low risk of bias) | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Kim et al. [] | 1996 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Probably yes | Probably yes |
| Kohnen et al. [] | 1996 | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably yes | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Kozera et al. [] | 2020 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Levkovitch-Verbin et al. [] | 2008 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Li et al. [] | 2008 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Mahajan et al. [] | 2021 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably no | Probably no | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Malecaze et al. [] | 2000 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Mastropasqua et al. [] | 1998 | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Paganelli et al. [] | 2004 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Paganelli et al. [] | 2009 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Probst et al. [] | 1993 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rabsilber et al. [] | 2007 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably no | Probably no | Probably no | Probably no | Probably no | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2000 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2000 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2001 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2001 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2001 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Rainer et al. [] | 2003 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Saari et al. [] | 2006 | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Sandoval et al. [] | 2006 | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Schwenn et al. [] | 2000 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Schwenn et al. [] | 2001 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Simaroj et al. [] | 2011 | Probably no | Probably no | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Sipos et al. [] | 2011 | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Solomon et al. [] | 1998 | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) |
| Stifter et al. [] | 2007 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Stifter et al. [] | 2010 | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Studeny et al. [] | 2014 | Definitely yes (low risk of bias) | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Waseem et al. [] | 2007 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Wedrich et al. [] | 1992 | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably no | Probably yes | Definitely yes (low risk of bias) | Probably yes |
| Wirtitsch et al. [] | 2007 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) |
| Wu et al. [] | 2018 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Probably no | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Yaylali et al. [] | 2004 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Probably yes |
| Zebardast et al. [] | 2020 | Probably no | Probably no | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Definitely no (high risk of bias) | Probably yes | Definitely yes (low risk of bias) | Probably yes |
| Ziakas et al. [] | 2009 | Probably no | Probably no | Probably no | Definitely no (high risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely yes (low risk of bias) | Definitely no (high risk of bias) | Definitely yes (low risk of bias) |
Table A3.
Surgical parameters for included studies.
Table A3.
Surgical parameters for included studies.
| Author | Year | Baseline IOP (mmHg), Mean (SD; Range), n Eyes | Post-op IOP (mmHg), Mean (SD); Min:25th: 50th:75th:Max Percentile | OVD Used (n Eyes) | Surgical Technique Performed | Method of IOP Measurement | Clear Corneal Thickness Measured (Yes/No) |
|---|---|---|---|---|---|---|---|
| Akbari et al. [] | 2021 | 16.2 (2.9) n = 88 | 1-day: 22.5 (5.6) n = 88 3-days: 17.5 (2.2) n = 88 | - | 2.8 mm temporal incision and 5–6 mm capsulorrhexis | Goldmann Applanation Tonometry | No |
| Akmaz et al. [] | 2023 | 13.9 (1.5) n = 32 14.2 (2.1) n = 33 | 1-day: 18.1 (1.4) n = 32 15.4 (3.2) n = 33 7-days: 14.5 (1.4) n = 32 14.1 (2.8) n = 33 | 1.4% Sodium Hyaluronate (32); None (33) | 2.8 mm incision and 5.0–5.5 mm capsulorhexis | Goldmann Applanation Tonometry | Yes |
| Arshinoff et al. [] | 2002 | 15.0 (2.4) n = 49 15.2 (2.3) n = 99 15.6 (2.4) n = 50 | 6 h: 17.6 (4.0) n = 49 18.1 (5.4) n = 99 18.2 (5.2) n = 50 1-day: 17.9 (4.7) n = 49 18.6 (5.3) n = 99 20.2 (6.2) n = 50 7-days: 14.4 (3.2) n = 49 14.3 (3.3) n = 99 14.1 (3.5) n = 50 | 1.0% Sodium Hyaluronate (49); 1.4% Sodium Hyaluronate (99); 2.3% Sodium Hyaluronate (50) | 2.8 mm incision | Goldmann Applanation Tonometry | Yes |
| Asano et al. [] | 2008 | 13.9 (3.0) n = 142 | 1-day: 14.3 (4.1) n = 142 11.6 (3.2) n = 142 | - | Small-incision | - | No |
| Auffarth et al. [] | 2017 | 15.3 (2.4) n = 111 15.2 (2.7) n = 109 | 6 h: 20.2 (6.6) n = 111 19.0 (6.7) n = 109 1-day: 16.0 (4.6) n = 111 15.2 (4.6) n = 109 7-days: 14.3 (2.8) n = 111 14.6 (4.4) n = 109 | 4.0% Chondroitin sulphate- 1.65% sodium hyaluronate (111); 2.2% Sodium hyaluronate—1.0% Sodium hyaluronate (109) | Self-sealing clear corneal incisions | Goldmann Applanation Tonometry | Yes |
| Balsak et al. [] | 2018 | 13.9 (3.2) n = 277 | 6 h: 24.0 (7.4) n = 277 1-day: 15.7 (5.0) n = 277 3-days:13.7 (4.0) n = 277 | 1.8% Sodium hyaluronate (277) | 2.75 mm clear corneal incision | Non-Contact Tonomtery | No |
| Borazan et al. [] | 2007 | 14.7 (2.3) n = 185 | 6 h: 19.1 (5.4) n = 185 1-day: 13.9 (3.9) n = 185 7-days: 14.3 (1.6) n = 185 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (185) | 3.2 mm clear corneal temporal incision, 5.0 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Camesaca et al. [] | 2007 | 15.6 (2.7) n = 286 | 1-day: 15.3 (4.5) n = 286 14.6 (5.2) n = 286 | Sodium hyaluronate 3.0%, 1.0% sodium hyaluronate, 4.0% chondroitin sulfate-3.0% sodium hyaluronate, 1.4% sodium hyaluronate, 2.3% sodium hyaluronate, or 1.8% sodium hyaluronate (286) | Temporal incision | Goldmann Applanation Tonometry | No |
| Cekic et al. [] | 1999 | 15.8 (3.0) n = 51 | 8 h: 15.7 (6.1) n = 51 1-day: 15.0 (4.8) n = 51 7-days: 14.4 (3.9) n = 51 | Sodium hyaluronate (51) | A clear corneal, curvilinear two-plane two-level incision | Goldmann Applanation Tonometry | No |
| Cekic et al. [] | 1999 | 15.1 (3.0) n = 58 | 1-day: 11.2 (2.4) n = 58 7-days: 11.5 (2.4) n = 58 | Chondroitin sulfate-sodium hyaluronate (58) | A clear corneal, curvilinear two-plane two-level incision, with either a 4.0 mm or 6.0 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Chang et al. [] | 2017 | 15.5 (14–19) n = 43 | 1-day: 18.8 (14–24) n = 43 21-days: 15.0 (13–17) n = 43 | 1.5% Sodium hyaluronate (43) | 2.2 mm clear corneal incision with either Standard or Low fluid settings | Goldmann Applanation Tonometry | Yes |
| Dieleman et al. [] | 2011 | 16.1 (3.2) n = 400 | 1-day: 15.5 (4.6) n = 400 30-days: 14.0 (2.9) n = 400 | 2.0% Hydroxypropyl methylcellulose (400) | 2.8 mm corneal or corneoscleral incision | Goldmann Applanation Tonometry | No |
| Dieleman et al. [] | 2012 | 16.0 (3.2) n = 400 | 1-day: 15.5 (4.6) n = 400 30-days: 14.0 (2.9) n = 400 | - | - | Goldmann Applanation Tonometry | No |
| el-Harazi et al. [] | 1998 | 17.2 (1.7) n = 58 | 1-day: 12.4 (2.6) n = 58 7-days: 15.3 (2.3) n = 58 | - | 5 mm incision | Goldmann Applanation Tonometry | No |
| Fernandez-Barrientos et al. [] | 2010 | 23.6 (1.5) n = 16 | 1-day: 26.4 (8.1) n = 16 14-days: 18.2 (4.2) n = 16 | 1.0% Sodium hyaluronate (16) | 2.8-mm temporal corneal incision | Goldmann Applanation Tonometry | No |
| Gungor et al. [] | 2014 | 14.9 (10–17) n = 60 | 1-day: 17.7 (12–24) n = 60 7-days: 14.3 (11–18) n = 60 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate and Sodium hyaluronate 1.0% (60) | 2.8 mm clear corneal incision and 5.0 mm capsulorhexis | Goldmann Applanation Tonometry | Yes |
| Haripriya et al. [] | 2019 | 14.3 (3.2) n = 1406 | 1-day: 13.6 (4.8) n = 1406 30-days: 13.6 (3.4) n = 1406 | - | 2.8 mm clear corneal temporal incision and 5 to 5.5 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Holzer et al. [] | 2001 | 16.0 (3.3) n = 19 16.6 (3.1) n = 30 14.5 (2.7) n = 12 15.4 (3.0) n = 20 | 6 h: 21.6 (4.5) n = 19 21.8 (7.1) n = 30 24.9 (7.1) n = 12 23.6 (7.5) n = 20 1-day: 17.1 (7.8) n = 19 19.3 (3.8) n = 30 15.7 (4.1) n = 12 17.1 (7.8) n = 20 7-days: 13.3 (2.6) n = 19 13.4 (3.4) n = 30 13.5 (2.6) n = 12 15.5 (3.5) n = 20 | 1.4% Sodium hyaluronate (19); 2.0% Hydroxypropyl methylcellulose (30); 2.3% Sodium hyaluronate (12); 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (20) | 2.5 mm corneoscleral superior incision | Goldmann Applanation Tonometry | No |
| Holzer et al. [] | 2002 | 15.6 (3.3) n = 60 | 1-day: 14.5 (5.4) n = 60 3-days: 13.1 (3.7) n = 60 | - | Clear corneal temporal incision | - | No |
| Honda et al. [] | 2004 | 13.8 (2.7) n = 44 | 1-day: 16.5 (5.5) n = 44 13.2 (3.7) n = 44 | - | Corneoscleral incision and continuous curvilinear capsulorhexis | - | No |
| Karalezli et al. [] | 2008 | 14.8 (2.4) n = 60 | 1-day: 15.6 (2.4) n = 60 7-days: 14.3 (1.4) n = 60 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate and 1.2% sodium hyaluronate (60) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Karalezli et al. [] | 2010 | 14.0 (2.0) n = 120 | 6 h: 17.9 (3.0) n = 120 1-day: 16.3 (2.7) n = 120 7-days: 14.0 (1.9) n = 120 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (120) | 3.2 mm clear corneal temporal incision and 5.0 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Kim et al. [] | 1996 | 14.5 (2.6) n = 24 | 1-day: 14.4 (3.4) n = 24 3-days: 14.0 (2.5) n = 24 | 1.4% Sodium hyaluronate (24) | Traditional Phacoemulsification | Pneumo-tonometry | No |
| Kohnen et al. [] | 1996 | 14.8 (2.3) n = 30 14.2 (2.2) n = 30 | 6 h: 16.8 (3.3) n = 30 16.2 (5.4) n = 30 1-day: 17.7 (3.7) n = 30 17.5 (6.8) n = 30 1.5-days: 15.6 (3.0) n = 30 14.3 (2.3) n = 30 2-days: 15.5 (3.4) n = 30 14.3 (2.5) n = 30 30-days: 14.6 (2.6) n = 30 14.1 (2.8) n = 30 | 1.0% sodium hyaluronate (30); 1.4% sodium hyaluronate (30) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Kozera et al. [] | 2020 | 21.9 (2.3) n = 36 | 1-day: 17.8 (4.3) n = 36 7-days: 16.8 (3.6) n = 36 | - | Traditional Phacoemulsification | Goldmann Applanation Tonometry | Yes |
| Levkovitch-Verbin et al. [] | 2008 | 15.7 (1.4) n = 122 | 4 h: 18.0 (4.3) n = 122 8 h: 17.0 (2.7) n = 122 1-day: 15.0 (2.1) n = 122 7-days: 13.9 (1.3) n = 122 | 1.2% Sodium hyaluronate (122) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Li et al. [] | 2008 | 16.7 (1.4) n = 70 16.5 (1.4) n = 70 | 1-day: 18.8 (1.0) n = 70 19.4 (1.2) n = 70 7-days: 12.4 (0.7) n = 70 13.0 (1.0) n = 70 | 0.1% chitosan (70); 1.4% Sodium hyaluronate (70) | - | Goldmann Applanation Tonometry | Yes |
| Mahajan et al. [] | 2021 | 15.9 (2.6) n = 150 | 1-day: 17.3 (5.8) n = 150 7-days: 15.8 (4.2) n = 150 | - | - | Non-Contact Tonometry | No |
| Malecaze et al. [] | 2000 | 14.9 (1.0) n = 50 | 1-day: 14.9 (1.2) n = 50 7-days: 14.7 (1.1) n = 50 | 1.4% Sodium hyaluronate (50) | 3.2 mm clear corneal incision | Goldmann Applanation Tonometry | No |
| Mastropasqua et al. [] | 1998 | 16.0 (2.0) n = 100 | 6 h: 19.9 (4.5) n = 100 1-day: 19.2 (4.7) n = 100 7-days: 16.4 (2.4) n = 100 | 1.4% Sodium hyaluronate (100) | 3.2 mm clear corneal superior incision and 5 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Paganelli et al. [] | 2004 | 14.2 (10–19) n = 100 | 1-day: 17.3 (12–24) n = 100 3-days: 15.4 (10–22) n = 100 | - | 2.75-mm clear corneal incision | Goldmann Applanation Tonometry | No |
| Paganelli et al. [] | 2009 | 14.0 (3.1) n = 135 | 1-day: 14.0 (3.9) n = 135 3-days: 13.2 (3.0) n = 132 | - | 2.75 mm clear corneal incision | Goldmann Applanation Tonometry | No |
| Probst et al. [] | 1993 | 14.7 (2.0) n = 25 17.1 (0.6) n = 25 | 1-day: 20.9 (2.0) n = 25 18.6 (2.0) n = 25 7-days: 15.4 (0.9) n = 25 13.4 (0.8) n = 25 | 1.6% Sodium hyaluronate (25); 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (25) | Superior limbal incision | - | Yes |
| Rabsilber et al. [] | 2007 | 14.8 (2.8) n = 34 | 1-day: 11.5 (2.7) n = 34 30-days: 11.9 (2.7) n = 34 | 1.4% Sodium hyaluronate (34) | Sealed capsule irrigation or Traditional | - | Yes |
| Rainer et al. [] | 2000 | 14.8 (2.4) n = 50 | 6 h: 16.8 (4.1) n = 50 1-day: 14.4 (4.2) n = 50 7-days: 13.7 (2.2) n = 50 | 1.0% Sodium hyaluronate (50) | 6.0 mm superior sutureless frown incision | Goldmann Applanation Tonometry | No |
| Rainer et al. [] | 2000 | 14.9 (2.5) n = 35 15.2 (2.9) n = 35 | 6 h: 20.1 (6.2) n = 35 25.2 (9.0) n = 35 1-day: 15.3 (3.9) n = 35 15.0 (3.4) n = 35 7-days: 13.5 (2.3) n = 35 13.5 (2.5) n = 35 | 2.3% Sodium hyaluronate (35); 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (35) | 3.5 mm temporal incision | Goldmann Applanation Tonometry | No |
| Rainer et al. [] | 2001 | 14.3 (2.6) n = 80 | 6 h: 20.6 (7.7) n = 80 1-day: 14.4 (3.8) n = 80 7-days: 13.7 (2.8) n = 80 | 1.0% Sodium hyaluronate (80) | 3.2 mm temporal incision | Goldmann Applanation Tonometry | No |
| Rainer et al. [] | 2001 | 13.9 (3.0) n = 60 | 6 h: 15.3 (4.4) n = 60 1-day: 12.8 (4.0) n = 60 7-days: 13.1 (3.0) n = 60 | 1.0% Sodium hyaluronate (60) | 3.5 mm temporal incision | Goldmann Applanation Tonometry | No |
| Rainer et al. [] | 2001 | 14.0 (2.8) n = 40 14.1 (2.8) n = 40 | 6 h: 19.0 (5.8) n = 40 18.8 (6.0) n = 40 1-day: 15.9 (3.9) n = 40 15.7 (4.7) n = 40 7-days: 13.8 (3.0) n = 40 13.6 (2.6) n = 40 | 2.0% Hydroxypropyl methylcellulose (40); 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (40) | 3.5 mm temporal incision | Goldmann Applanation Tonometry | No |
| Rainer et al. [] | 2003 | 15.4 (2.5) n = 76 | 6 h: 21.8 (6.5) n = 76 1-day: 14.8 (4.2) n = 76 7-days: 14.5 (3.2) n = 76 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (76) | 3.5 mm temporal incision | Goldmann Applanation Tonometry | No |
| Saari et al. [] | 2006 | 17.9 (3.0) n = 20 | 1-day: 15.7 (5.5) n = 20 3-days: 14.6 (4.5) n = 20 | 1.0% Sodium hyaluronate (20) | 3.5 mm sclerotunnel superior incision and 5.0 mm capsulorhexis | Goldmann Applanation Tonometry | No |
| Sandoval et al. [] | 2006 | 15.1 (3.5) n = 40 | 1-day: 16.6 (5.2) n = 40 3-days: 12.7 (1.9) n = 40 | - | Traditional Phacoemulsification | - | No |
| Schwenn et al. [] | 2000 | 13.5 (2.0) n = 20 14.6 (3.0) n = 28 | 4 h: 18.1 (6.7) n = 20 27.5 (10.1) n = 28 6 h: 16.4 (5.1) n = 20 23.1 (8.5) n = 28 1-day: 12.3 (3.0) n = 20 14.5 (5.5) n = 28 2-days: 9.6 (2.2) n = 20 12.3 (3.5) n = 28 3-days: 9.8 (2.2) n = 20 12.2 (3.8) n = 28 | 2.3% Sodium hyaluronate (20); 4.0% Chondroitin sulphate-3.0% sodium hyaluronate (28) | 3.2 mm inverse curved superior incision | - | Yes |
| Schwenn et al. [] | 2001 | 14.4 (2.6) n = 100 | 6 h: 20.9 (7.6) n = 100 1-day: 15.7 (4.9) n = 100 2-days: 13.5 (3.1) n = 100 3-days: 13.4 (3.0) n = 100 | 2.0% Hydroxypropyl methylcellulose (100) | Temporal incision being either clear corneal or sclerocorneal incision | Goldmann Applanation Tonometry | No |
| Simaroj et al. [] | 2011 | 13.9 (2.2) n = 60 | 1-day: 13.1 (2.4) n = 60 7-days: 12.6 (2.0) n = 60 | - | 3-mm clear corneal incision | Goldmann Applanation Tonometry | No |
| Sipos et al. [] | 2011 | 16.4 (2.4) n = 60 | 1-day: 17.0 (1.6) n = 60 7-days: 15.2 (1.6) n = 60 | - | - | - | No |
| Solomon et al. [] | 1998 | 15.3 (2.6) n = 41 | 6 h: 18.1 (7.1) n = 41 1-day: 16.3 (3.9) n = 41 7-days: 13.9 (2.6) n = 41 | 1.4% Sodium hyaluronate (41) | Clear corneal incision | Goldmann Applanation Tonometry | Yes |
| Stifter et al. [] | 2007 | 13.4 (2.5) n = 100 | 1 h: 19.0 (3.3) n = 100 2 h: 18.4 (2.8) n = 100 4 h:16.8 (2.4) n = 100 6 h: 15.8 (2.7) n = 100 8 h: 14.9 (2.8) n = 100 1-day: 14.2 (2.6) n = 100 7-days: 14.4 (2.1) n = 100 | 1.0% Sodium hyaluronate (100) | Combined Primary posterior continuous curvilinear capsulorhexis and posterior optic buttonholing or Conventional in-the-bag IOL implantation | Goldmann Applanation Tonometry | No |
| Stifter et al. [] | 2010 | 13.8 (1.9) n = 60 | 1 h: 20.8 (6.7) n = 60 2 h: 19.4 (5.9) n = 60 4 h: 18.5 (5.2) n = 60 6 h: 17.6 (4.5) n = 60 8 h: 16.5 (3.1) n = 60 1-day: 15.5 (2.4) n = 60 7-days: 14.1 (2.2) n = 60 | 1.0% Sodium hyaluronate and 2.0% Hydroxypropyl methylcellulose (60) | Combined Primary posterior capsulorhexis and posterior optic buttonholing or Conventional in-the-bag IOL implantation | Goldmann Applanation Tonometry | No |
| Studeny et al. [] | 2014 | 16.8 (3.9) n = 96 16.4 (3.9) n = 96 | 2 h: 10.2 (6.8) n = 96 9.9 (7.0) n = 96 1-day: 14.5 (5.6) n = 96 15.5 (5.8) n = 96 30-days: 13.2 (3.5) n = 96 13.1 (3.4) n = 96 | 2.0% Hydroxypropyl methylcellulose (96); 1.0% Sodium hyaluronate and 2.0% Hydroxypropyl methylcellulose (96) | Either hydroimplantation of IOL or OVD use in IOL implantation | Non-Contact Tonometry | No |
| Waseem et al. [] | 2007 | 14.3 (2) n = 46 14.1 (1.9) n = 45 | 1-day: 18.8 (2.9) n = 46 16.9 (2.6) n = 45 7-days: 14.7 (1.6) n = 46 14.4 (1.7) n = 45 | 1.0% Sodium hyaluronate (46); 2.0% Hydroxypropyl methylcellulose (45) | 3.2 mm temporal limbal incision | Goldmann Applanation Tonometry | No |
| Wedrich et al. [] | 1992 | 14.2 (3.2) n = 90 | 6 h: 15.1 (8.2) n = 90 18 h: 14.3 (6.5) n = 90 7-days: 13.8 (2.5) n = 90 | 1.0% Sodium hyaluronate (90) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Wirtitsch et al. [] | 2007 | 16.6 (2.6) n = 88 | 6 h: 18.7 (5.4) n = 88 1-day: 15.2 (3.5) n = 88 7-days: 16.0 (2.9) n = 88 | 1.0% Sodium hyaluronate (88) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Wu et al. [] | 2018 | 14.5 (2.6) n = 99 | 1-day: 15.2 (5.0) n = 99 7-days: 14.6 (3.3) n = 99 | 1.0% Sodium hyaluronate (99) | Standard 3.0 mm small incision phacoemulsification or Coaxial 2.2 mm micro-incision Fusion Phaco complex phacoemulsification | Non-Contact Tonometry | Yes |
| Yaylali et al. [] | 2004 | 13.3 (2.5) n = 48 | 1-day: 14.7 (5.6) n = 48 3-days: 11.3 (1.7) n = 48 | 4.0% Chondroitin sulphate-3.0% sodium hyaluronate and 1.2% Sodium hyaluronate (48) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
| Zebardast et al. [] | 2020 | 25.4 (2.9) n = 187 | 1-day: 27.6 (10.2) n = 187 7-days: 20.8 (6.3) n = 187 | - | Traditional Phacoemulsification | Goldmann Applanation Tonometry | Yes |
| Ziakas et al. [] | 2009 | 14.5 (3.0) n = 30 | 1-day: 12.7 (4.5) n = 30 7-days: 13.2 (2.3) n = 30 | Sodium hyaluronate (30) | Traditional Phacoemulsification | Goldmann Applanation Tonometry | No |
Table A4.
Medications administered for included studies.
Table A4.
Medications administered for included studies.
| Author | Year | Pre-Operative Medications (n Eyes) | Intra-Operative Medications (n Eyes) | Post-Operative Medications (n Eyes) |
|---|---|---|---|---|
| Akbari et al. [] | 2021 | None | None | Chloramphenicol 5%, betamethasone 0.1%, and ketorolac tomethamine 0.5%(46) Or Chloramphenicol 5%, and betamethasone 0.1% (42) |
| Akmaz et al. [] | 2023 | None | 0.1 cc moxifloxacin (65) | None |
| Arshinoff et al. [] | 2002 | Ofloxacin 0.3%, and diclofenac 0.1% eyedrops (198) | None | Tobramycin and dexamethasone eyedrops (198) |
| Asano et al. [] | 2008 | Diclofenac sodium 0.1% (71) or Betamethasone sodium 0.1% (71) | None | Diclofenac sodium 0.1% (71) Or Betamethasone sodium 0.1% (71) |
| Auffarth et al. [] | 2017 | - | - | - |
| Balsak et al. [] | 2018 | None | Cefurozime axetil 0.1% (277) | Brimonidine-timolol, tobramycin and dexamethasone (231) Or Tobramycin and dexamethasone (46) |
| Borazan et al. [] | 2007 | Diclofenac (185) | None (153) or Carbachol (32) | Acetazolamide 250 mg, ofloxacin 0.3% and prednisolone acetate 1% eyedrops (185) With either Topical brinzolamide 1% (30), Brimonidine 0.2% (32), Oral acetazolamide 250 mg (30), Timolol maleate 0.5% (30), Or nothing else (63) |
| Camesaca et al. [] | 2007 | Fluoroquinolone (286) | None | Chloramphenicol 0.25% and betamethasone 0.13% gel (143) Or Tobramycin 0.3% and dexamethasone 0.1% (143) |
| Cekic et al. [] | 1999 | None | None | 0.5 mL balanced salt solution (24) Or 0.5 mL carbachol 0.01% (27) |
| Cekic et al. [] | 1999 | None | Carbachol (58) | 20 mg gentamicin and 2 mg betamethasone (58) |
| Chang et al. [] | 2017 | None | 0.2 mg moxifloxacin (43) | Dexamethasone (43) |
| Dieleman et al. [] | 2011 | None | None | Betamethasone acetate 5.7 mg/mL (200) Or Dexamethasone 0.1% (200) |
| Dieleman et al. [] | 2012 | None | None | Physostigmine, and dexamethasone (199) Or Dexamethasone (201) |
| el-Harazi et al. [] | 1998 | None | None | Diclofenac sodium 0.1% (19) Or Ketorolac tromethamine 0.5% (19) Or Prednisolone acetate 1% (20) |
| Fernandez-Barrientos et al. [] | 2010 | 1 mg/mL tetracaine chloride and 4mg/mL oxybuprocainechloride (16) | None | None |
| Gungor et al. [] | 2014 | None | None | Triamcinolone acetonide 2 mg/0.05 mL (30) Or Dexamethasone (0.4 mg/0.1 mL (30) |
| Haripriya et al. [] | 2019 | Topical ofloxacin 0.3% (1406) | None | Topical ofloxacin 0.3% and prednisolone acetate 1% (1406) |
| Holzer et al. [] | 2001 | - | - | - |
| Holzer et al. [] | 2002 | Ofloxacin 0.3% (60) | Epinephrine and carbachol (60) | Loteprednol etabonate 0.5% and ofloxacin 0.3% (30) Or Ketorolac tromethamine 0.5% and ofloxacin 0.3% (30) |
| Honda et al. [] | 2004 | - | - | Topical mixture of unspecified antibiotics and steroids (44) |
| Karalezli et al. [] | 2008 | None | None (30) Or 1 mg intracameral triamcinolone acetonide (30) | Topical prednisolone acetate 1% and topical ofloxacin 0.3% (30) Or Topical ofloxacin 0.3% (30) |
| Karalezli et al. [] | 2010 | None | None | None (60) Or 1mg triamcinolone acetonide (60) |
| Kim et al. [] | 1996 | Tobramycin (24) | None | Topical 0.1% fluorometholone (24) |
| Kohnen et al. [] | 1996 | Unspecified antibiotics eye drops and oral 250 mg acetazolamide (60) | None | Dexamethasone, polymyxin, neomycin, and unspecified steroid/antibiotic drops (60) |
| Kozera et al. [] | 2020 | None | None | Loteprednol and Moxifloksacinum (36) |
| Levkovitch-Verbin et al. [] | 2008 | Unspecified anti-glaucoma medications (33) Or None (89) | None | Dexamethasone 0.1% eye drops and chloramphenicol ointment (122) With either Timolol maleate (60), unspecified anti-glaucoma medications (33), and/or nothing else (44) |
| Li et al. [] | 2008 | - | - | - |
| Mahajan et al. [] | 2021 | - | - | Topical difluprednate 0.05% (50) Or Topical dexamethasone 0.1% (50) Or Topical prednisolone 1% (50) |
| Malecaze et al. [] | 2000 | None | None | Gentamicin eye drops (50) |
| Mastropasqua et al. [] | 1998 | - | None | - |
| Paganelli et al. [] | 2004 | None | None (50) Or 40-mg triamcinolone acetonide (50) | Prednisolone acetate 1% (50) Or None |
| Paganelli et al. [] | 2009 | None | None (67) Or 25 mg triamcinolone and 2 mg ciprofloxacin (68) | Prednisolone acetate 1% and ciprofloxacin hydrochloride 0.3% (67) Or None (68) |
| Probst et al. [] | 1993 | None | None | None (42) Or Topical Beta blocker (8) |
| Rabsilber et al. [] | 2007 | None | None | None |
| Rainer et al. [] | 2000 | Diclofenac (50) | None | Betamethasone-neomycin ointment, diclofenac and prednisolone acetate (50) With either Apraclonidine 0.5% (25) Or dorzolamide 2% (25) |
| Rainer et al. [] | 2000 | Diclofenac (70) | None | Gentamicin-prednisolone ointment, and diclofenac and prednisolone acetate 0.5% eyedrops (70) |
| Rainer et al. [] | 2001 | Diclofenac (80) | None | Prednisolone acetate 0.5% ointment and diclofenac and prednisolone acetate 0.5% eyedrops (80) With either brimonidine 0.2% eye drops (40) Or prednisolone acetate 0.5% ointment (40) |
| Rainer et al. [] | 2001 | Diclofenac eye drops (80) | None | Prednisolone ointment and diclofenac and prednisolone acetate 0.5% eyedrops (80) |
| Rainer et al. [] | 2001 | Diclofenac eyedrops (60) | None | Acetate 0.5% ointment, and diclofenac and prednisolone acetate 0.5% eyedrops (60) With either Prednisolone fixed dorzolamide–timolol combination eye drops (30), Or latanoprost eye drops (30) |
| Rainer et al. [] | 2003 | None | None | None (38) Or Fixed dorzolamide–timolol combination (38) |
| Saari et al. [] | 2006 | 250 mg Oral acetazolamide (20) | None | 0.7% or 0.1% dexamethasone with chloramphenicol eye drops, and dexamethasone alcohol and neomycin sulphate ointment (20) |
| Sandoval et al. [] | 2006 | Ketorolac 0.4% or 0.5%, eye drops (40) | None | Ketorolac 0.4% or 0.5% and ofloxacin 0.3% (40) |
| Schwenn et al. [] | 2000 | Topical diclofenac (48) | None | Prednisolone acetate eye drops and ointment, and gentamicin eye drops (48) |
| Schwenn et al. [] | 2001 | None | None | Prednisolone acetate eyedrops, gentamicin sulfate, and 5 mg/g prednisolone pivalate ointment (100) |
| Simaroj et al. [] | 2011 | None | None (30) Or Intracameral triamcinolone acetonide and gentamicin (30) | Topical 0.1% dexamethasone-0.3% tobramycin combination (30) Or Topical tobramycin (30) |
| Sipos et al. [] | 2011 | Diclofenac eye drops (60) | None | Diclofenac sodium and gentamicin eyedrops (60) With either Low-viscosity tear replacement eye drops (11), high-viscosity tear replacement eye drops (9), 0.3 mg dexamethasone and 3 mg gentamicin sulfate ointment (10), or nothing else (30) |
| Solomon et al. [] | 1998 | None | None (20) Or Intracameral carbachol 0.01% (21) | Unspecified topical antibiotic-corticosteroid combination (41) |
| Stifter et al. [] | 2007 | None | None | Dexamethasone-gentamicin ointment, diclofenac sodium and prednisolone acetate 0.5% eyedrops (100) With either Dorzolamide hydrochloride 2.0%–timolol maleate 0.5% eye drops (50) Or Nothing else (50) |
| Stifter et al. [] | 2010 | Diclofenac eye drops (60) | None | None |
| Studeny et al. [] | 2014 | None | None | None |
| Waseem et al. [] | 2007 | None | None | Norfloxacin 0.3%, dexamethasone eye 0.1% drops, and Fusidic acid eye ointment (91) |
| Wedrich et al. [] | 1992 | None | None (30) Or Intracameral carbachol (30) Or Intracameral acetylcholine 1% | Topical steroids and indomethacin (90) |
| Wirtitsch et al. [] | 2007 | None | Fixed dorzolamide–timolol combination eye drop (88) | Prednisolone acetate 1% and diclofenac eye drops (88) |
| Wu et al. [] | 2018 | None | None | Levofloxacin and prednisolone eye drops (99) |
| Yaylali et al. [] | 2004 | None | None | Ofloxacin 0.3% (48) With either prednisolone acetate 1% eyedrops (21) Or topical rimexolone 1% (27) |
| Zebardast et al. [] | 2020 | None | None | Unspecified topical antibiotics and corticosteroids (187) |
| Ziakas et al. [] | 2009 | None | None (15) Or Trypan Blue (15) | 1 tablet of acetazolamide 250 mg, and dexamethasone 1mg/mL and chloramphenicol 5 mg/mL eye drops (30) |
References
- Liu, Y.C.; Wilkins, M.; Kim, T.; Malyugin, B.; Mehta, J.S. Cataracts. Lancet 2017, 390, 600–612. [Google Scholar] [CrossRef] [PubMed]
- Canadian National Institute for the Blind (CNIB). Blindness in Canada. 2023. Available online: https://www.cnib.ca/en/sight-loss-info/blindness/blindness-canada?region=on (accessed on 21 August 2024).
- Hatch, W.V.; Campbell, E.D.L.; Bell, C.M.; El-Defrawy, S.R.; Campbell, R.J. Projecting the growth of cataract surgery during the next 25 years. Arch. Ophthalmol. 2012, 130, 1479–1481. [Google Scholar] [CrossRef] [PubMed]
- Gu, D.; Andreev, K.; Dupre, M.E. Major Trends in Population Growth Around the World. China CDC Wkly. 2021, 3, 604–613. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Yan, W.; Fotis, K.; Prasad, N.M.; Lansingh, V.C.; Taylor, H.R.; Finger, R.P.; Facciolo, D.; He, M. Cataract Surgical Rate and Socioeconomics: A Global Study. Investig. Ophthalmol. Vis. Sci. 2016, 57, 5872–5881. [Google Scholar] [CrossRef] [PubMed]
- American Academy of Ophthalmology. Cataract in the Adult Eye PPP. 2021. Available online: https://www.aao.org/education/preferred-practice-pattern/cataract-in-adult-eye-ppp-2021-in-press (accessed on 21 August 2024).
- Thompson, J.; Lakhani, N. Cataracts. Prim. Care Clin. Off. Pract. 2015, 42, 409–423. [Google Scholar] [CrossRef]
- Malvankar-Mehta, M.S.; Fu, A.; Subramanian, Y.; Hutnik, C. Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery. J. Ophthalmol. 2020, 780, 1093. [Google Scholar] [CrossRef]
- Chan, E.; Mahroo, O.A.R.; Spalton, D.J. Complications of cataract surgery. Clin. Exp. Optom. 2010, 93, 379–389. [Google Scholar] [CrossRef]
- Ahmed, I.I.; Kranenmann, C.; Chipman, M.; Malam, F. Revisiting early postoperative follow-up after phacoemulsification. J. Cataract. Refract. Surg. 2002, 28, 100–108. [Google Scholar] [CrossRef]
- Todorović, M.; Šarenac Vulović, T.; Petrović, N.; Todorović, D.; Srećković, S. Intraocular pressure changes after uneventful phacoemulsification in early postoperative period in healthy eyes. Acta Clin. Croat. 2019, 58, 467–472. [Google Scholar] [CrossRef]
- Grzybowski, A.; Kanclerz, P. Do we need day-1 postoperative follow-up after cataract surgery? Graefes Arch. Clin. Exp. Ophthalmol. 2019, 257, 855–861. [Google Scholar] [CrossRef]
- CLARITY Group at McMaster University. Tools to Assess Risk of Bias in Cohort and Case Control Studies; Randomized Controlled Trials; and Longitudinal Symptom Research Studies Aimed at the General Population. 2024. Available online: https://www.distillersr.com/resources/methodological-resources/tool-to-assess-risk-of-bias-in-randomized-controlled-trials-distillersr (accessed on 21 August 2024).
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, 71. [Google Scholar] [CrossRef] [PubMed]
- Akbari, M.; Moghadam, R.S.; Mohamadpour, A. The Effect of Ketorolac Eye Drop on Inflammation and Anterior Segment Complications after Cataract Surgery in Pseudoexfoliation Syndrome; a Randomized Clinical Trial. Pak. J. Med. Health Sci. 2021, 15, 1098–1104. [Google Scholar]
- Akmaz, B.; Kilic, D.; Duru, N. The Safety and Efficacy of Phacoemulsification Surgery in Uncomplicated Cataracts with and without an Ophthalmic-Viscosurgical-Device. Eur. J. Ophthalmol. 2023, 33, 269–277. [Google Scholar] [CrossRef] [PubMed]
- Arshinoff, S.A.; Albiani, D.A.; Taylor-Laporte, J. Intraocular Pressure after Bilateral Cataract Surgery Using Healon, Healon5, and Healon GV. J. Cataract. Refract. Surg. 2002, 28, 617–625. [Google Scholar] [CrossRef]
- Asano, S.; Miyake, K.; Ota, I.; Sugita, G.; Kimura, W.; Sakka, Y.; Yabe, N. Reducing Angiographic Cystoid Macular Edema and Blood-Aqueous Barrier Disruption after Small-Incision Phacoemulsification and Foldable Intraocular Lens Implantation: Multicenter Prospective Randomized Comparison of Topical Diclofenac 0.1% and Betamethason. J. Cataract. Refract. Surg. 2008, 34, 57–63. [Google Scholar] [CrossRef]
- Auffarth, G.U.; Auerbach, F.N.; Rabsilber, T.; Gegundez, J.A.; Cuina, R.; Renard, Y.; Vinciguerra, P.; Camesasca, F.; Van Cauwenberge, F.; Amzallag, T.; et al. Comparison of the Performance and Safety of 2 Ophthalmic Viscosurgical Devices in Cataract Surgery. J. Cataract. Refract. Surg. 2017, 43, 87–94. [Google Scholar] [CrossRef]
- Balsak, S.; Kaydu, A.; Erdem, S.; Fuat Alakus, M.; Ozkurt, Z.G. Brimonidine-Timolol versus Brinzolamide-Timolol for Treatment of Elevated Intraocular Pressure after Phacoemulsification Surgery. Int. Ophthalmol. 2018, 38, 1583–1589. [Google Scholar] [CrossRef] [PubMed]
- Borazan, M.; Karalezli, A.; Akman, A.; Akova, Y.A. Effect of Antiglaucoma Agents on Postoperative Intraocular Pressure after Cataract Surgery with Viscoat. J. Cataract. Refract. Surg. 2007, 33, 1941–1945. [Google Scholar] [CrossRef]
- Camesasca, F.I.; Bianchi, C.; Beltrame, G.; Caporossi, A.; Piovella, M.; Rapisarda, A.; Tassinari, G.; Zeppa, L. Italian Betamethasone-Chloramphenicol vs. Dexamethasone-Tobramycin Combination Study Group Control of Inflammation and Prophylaxis of Endophthalmitis after Cataract Surgery: A Multicenter Study. Eur. J. Ophthalmol. 2007, 17, 733–742. [Google Scholar] [CrossRef]
- Cekic, O.; Batman, C. Effect of Capsulorhexis Size on Postoperative Intraocular Pressure. J. Cataract. Refract. Surg. 1999, 25, 416–419. [Google Scholar] [CrossRef]
- Cekic, O.; Batman, C. Effect of Intracameral Carbachol on Intraocular Pressure Following Clear Corneal Phacoemulsification. Eye 1999, 13 Pt 2, 209–211. [Google Scholar] [CrossRef] [PubMed]
- Chang, A.; Fridberg, A.; Kugelberg, M. Comparison of Phacoemulsification Cataract Surgery with Low versus Standard Fluidic Settings and the Impact on Postoperative Parameters. Eur. J. Ophthalmol. 2017, 27, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Dieleman, M.; Wubbels, R.J.; van Kooten-Noordzij, M.; de Waard, P.W.T. Single Perioperative Subconjunctival Steroid Depot versus Postoperative Steroid Eyedrops to Prevent Intraocular Inflammation and Macular Edema after Cataract Surgery. J. Cataract. Refract. Surg. 2011, 37, 1589–1597. [Google Scholar] [CrossRef] [PubMed]
- Dieleman, M.; Wubbels, R.J.; De Waard, P.W.T. Miotics after Modern Cataract Surgery Are History. J. Ocul. Pharmacol. Ther. 2012, 28, 98–101. [Google Scholar] [CrossRef] [PubMed]
- el-Harazi, S.M.; Ruiz, R.S.; Feldman, R.M.; Villanueva, G.; Chuang, A.Z. A Randomized Double-Masked Trial Comparing Ketorolac Tromethamine 0.5%, Diclofenac Sodium 0.1%, and Prednisolone Acetate 1% in Reducing Post-Phacoemulsification Flare and Cells. Ophthalmic Surg. Lasers 1998, 29, 539–544. [Google Scholar] [CrossRef]
- Fernandez-Barrientos, Y.; Garcia-Feijoo, J.; Martinez-de-la-Casa, J.M.; Pablo, L.E.; Fernandez-Perez, C.; Garcia Sanchez, J. Fluorophotometric Study of the Effect of the Glaukos Trabecular Microbypass Stent on Aqueous Humor Dynamics. Investig. Ophthalmol. Vis. Sci. 2010, 51, 3327–3332. [Google Scholar] [CrossRef]
- Gungor, S.G.; Bulam, B.; Akman, A.; Colak, M. Comparison of Intracameral Dexamethasone and Intracameral Triamcinolone Acetonide Injection at the End of Phacoemulsification Surgery. Indian J. Ophthalmol. 2014, 62, 861–864. [Google Scholar] [CrossRef]
- Haripriya, A.; Ramulu, P.Y.; Chandrashekharan, S.; Venkatesh, R.; Narendran, K.; Shekhar, M.; Ramakrishnan, R.; Ravindran, R.D.; Robin, A.L. The Aravind Pseudoexfoliation Study: Surgical and First-Year Postoperative Results in Eyes without Phacodonesis and Nonmiotic Pupils. Ophthalmology 2019, 126, 362–371. [Google Scholar] [CrossRef]
- Holzer, M.P.; Tetz, M.R.; Auffarth, G.U.; Welt, R.; Volcker, H.E. Effect of Healon5 and 4 Other Viscoelastic Substances on Intraocular Pressure and Endothelium after Cataract Surgery. J. Cataract. Refract. Surg. 2001, 27, 213–218. [Google Scholar] [CrossRef]
- Holzer, M.P.; Solomon, K.D.; Sandoval, H.P.; Vroman, D.T. Comparison of Ketorolac Tromethamine 0.5% and Loteprednol Etabonate 0.5% for Inflammation after Phacoemulsification: Prospective Randomized Double-Masked Study. J. Cataract. Refract. Surg. 2002, 28, 93–99. [Google Scholar] [CrossRef]
- Honda, S.; Matsuo, A.; Toda, H.; Saito, I. Effect of Eye Patching on Postoperative Inflammation after Cataract Surgery. J. Cataract. Refract. Surg. 2004, 30, 273–274. [Google Scholar] [CrossRef] [PubMed]
- Karalezli, A.; Borazan, M.; Akova, Y.A. Intracameral Triamcinolone Acetonide to Control Postoperative Inflammation Following Cataract Surgery with Phacoemulsification. Acta Ophthalmol. 2008, 86, 183–187. [Google Scholar] [CrossRef] [PubMed]
- Karalezli, A.; Borazan, M.; Kucukerdonmez, C.; Akman, A.; Akova, Y.A. Effect of Intracameral Triamcinolone Acetonide on Postoperative Intraocular Pressure after Cataract Surgery. Eye 2010, 24, 619–623. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.W. Comparative Study of Intraocular Pressure Change after Cataract Surgery: Phacoemulsification and Extracapsular Cataract Extraction. Korean J. Ophthalmol. KJO 1996, 10, 104–108. [Google Scholar] [CrossRef] [PubMed]
- Kohnen, T.; von Ehr, M.; Schutte, E.; Koch, D.D. Evaluation of Intraocular Pressure with Healon and Healon GV in Sutureless Cataract Surgery with Foldable Lens Implantation. J. Cataract. Refract. Surg. 1996, 22, 227–237. [Google Scholar] [CrossRef] [PubMed]
- Kozera, M.; Konopinska, J.; Mariak, Z.; Rekas, M. Effectiveness of iStent Trabecular Micro-Bypass System Combined with Phacoemulsification vs. Phacoemulsification Alone in Patients with Glaucoma and Cataract Depending on the Initial Intraocular Pressure. Ophthalmic Res. 2020, 64, 327–336. [Google Scholar] [CrossRef]
- Levkovitch-Verbin, H.; Habot-Wilner, Z.; Burla, N.; Melamed, S.; Goldenfeld, M.; Bar-Sela, S.M.; Sachs, D. Intraocular Pressure Elevation within the First 24 Hours after Cataract Surgery in Patients with Glaucoma or Exfoliation Syndrome. Ophthalmology 2008, 115, 104–108. [Google Scholar] [CrossRef]
- Li, Y.; Cheng, J.-W.; Wei, R.-L.; Hou, C.-L.; Wang, W.-B.; Gu, Q.-S.; Cai, J.-P. Intraocular Pressure and Endothelium Cell Counts after Cataract Surgery with Chitosan and Sodium Hyaluronate (Healon GV): 3-Year Follow-up Results of a Randomised Clinical Trial. Adv. Ther. 2008, 25, 422–429. [Google Scholar] [CrossRef]
- Mahajan, S.; Kai, S.; Choudhary, S.; Bala, K.; Sahni, B. Evaluation of Intraocular Pressure Changes with Topical Dexamethasone 0.1%, Prednisolone 1% and Difluprednate 0.05% Postcataract Surgery-A Randomised Clinical Trial. J. Clin. Diagn. Res. 2021, 15, 15071. [Google Scholar] [CrossRef]
- Malecaze, F.A.; Deneuville, S.F.; Julia, B.J.; Daurin, J.G.; Chapotot, E.M.; Grandjean, H.M.; Arne, J.L.; Rascol, O. Pain Relief with Intracameral Mepivacaine during Phacoemulsification. Br. J. Ophthalmol. 2000, 84, 171–174. [Google Scholar] [CrossRef][Green Version]
- Mastropasqua, L.; Carpineto, P.; Ciancaglini, M.; Falconio, G. Intraocular Pressure Changes after Phacoemulsification and Foldable Silicone Lens Implantation Using Healon GV. Ophthalmologica 1998, 212, 318–321. [Google Scholar] [CrossRef]
- Paganelli, F.; Cardillo, J.A.; Melo, L.A.S.J.; Oliveira, A.G.; Skaf, M.; Costa, R.A. Brazilian Ocular Pharmacology and Pharmaceutical Technology Research Group A Single Intraoperative Sub-Tenon’s Capsule Triamcinolone Acetonide Injection for the Treatment of Post-Cataract Surgery Inflammation. Ophthalmology 2004, 111, 2102–2108. [Google Scholar] [CrossRef] [PubMed]
- Paganelli, F.; Cardillo, J.A.; Melo, L.A.S.J.; Lucena, D.R.; Silva, A.A.J.; Oliveira, A.G.; Hofling-Lima, A.L.; Nguyen, Q.D.; Kuppermann, B.D.; Belfort, R.J.; et al. A Single Intraoperative Sub-Tenon’s Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3041–3047. [Google Scholar] [CrossRef] [PubMed]
- Probst, L.E.; Nichols, B.D. Corneal Endothelial and Intraocular Pressure Changes after Phacoemulsification with Amvisc Plus and Viscoat. J. Cataract. Refract. Surg. 1993, 19, 725–730. [Google Scholar] [CrossRef] [PubMed]
- Rabsilber, T.M.; Limberger, I.-J.; Reuland, A.J.; Holzer, M.P.; Auffarth, G.U. Long-Term Results of Sealed Capsule Irrigation Using Distilled Water to Prevent Posterior Capsule Opacification: A Prospective Clinical Randomised Trial. Br. J. Ophthalmol. 2007, 91, 912–915. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Rainer, G.; Menapace, R.; Findl, O.; Georgopoulos, M.; Kiss, B.; Heinze, G. Randomised Fellow Eye Comparison of the Effectiveness of Dorzolamide and Apraclonidine on Intraocular Pressure Following Phacoemulsification Cataract Surgery. Eye 2000, 14, 757–760. [Google Scholar] [CrossRef][Green Version]
- Rainer, G.; Menapace, R.; Findl, O.; Georgopoulos, M.; Kiss, B.; Petternel, V. Intraocular Pressure after Small Incision Cataract Surgery with Healon5 and Viscoat. J. Cataract. Refract. Surg. 2000, 26, 271–276. [Google Scholar] [CrossRef]
- Rainer, G.; Menapace, R.; Findl, O.; Petternel, V.; Kiss, B.; Georgopoulos, M. Effect of Topical Brimonidine on Intraocular Pressure after Small Incision Cataract Surgery. J. Cataract. Refract. Surg. 2001, 27, 1227–1231. [Google Scholar] [CrossRef]
- Rainer, G.; Menapace, R.; Findl, O.; Petternel, V.; Kiss, B.; Georgopoulos, M. Intraindividual Comparison of the Effects of a Fixed Dorzolamide-Timolol Combination and Latanoprost on Intraocular Pressure after Small Incision Cataract Surgery. J. Cataract. Refract. Surg. 2001, 27, 706–710. [Google Scholar] [CrossRef]
- Rainer, G.; Menapace, R.; Findl, O.; Kiss, B.; Petternel, V.; Georgopoulos, M.; Schneider, B. Intraocular Pressure Rise after Small Incision Cataract Surgery: A Randomised Intraindividual Comparison of Two Dispersive Viscoelastic Agents. Br. J. Ophthalmol. 2001, 85, 139–142. [Google Scholar] [CrossRef]
- Rainer, G.; Menapace, R.; Findl, O.; Sacu, S.; Schmid, K.; Petternel, V.; Kiss, B.; Georgopoulos, M. Effect of a Fixed Dorzolamide-Timolol Combination on Intraocular Pressure after Small-Incision Cataract Surgery with Viscoat. J. Cataract. Refract. Surg. 2003, 29, 1748–1752. [Google Scholar] [CrossRef] [PubMed]
- Saari, K.M.; Nelimarkka, L.; Ahola, V.; Loftsson, T.; Stefansson, E. Comparison of Topical 0.7% Dexamethasone-Cyclodextrin with 0.1% Dexamethasone Sodium Phosphate for Postcataract Inflammation. Graefe’s Arch. Clin. Exp. Ophthalmol. = Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2006, 244, 620–626. [Google Scholar] [CrossRef]
- Sandoval, H.P.; De Castro, L.E.F.; Vroman, D.T.; Solomon, K.D. Evaluation of 0.4% Ketorolac Tromethamine Ophthalmic Solution versus 0.5% Ketorolac Tromethamine Ophthalmic Solution after Phacoemulsification and Intraocular Lens Implantation. J. Ocul. Pharmacol. Ther. 2006, 22, 251–257. [Google Scholar] [CrossRef]
- Schwenn, O.; Dick, H.B.; Krummenauer, F.; Christmann, S.; Vogel, A.; Pfeiffer, N. Healon5 versus Viscoat during Cataract Surgery: Intraocular Pressure, Laser Flare and Corneal Changes. Graefe’s Arch. Clin. Exp. Ophthalmol. = Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2000, 238, 861–867. [Google Scholar] [CrossRef] [PubMed]
- Schwenn, O.; Dick, H.B.; Krummenauer, F.; Krist, R.; Pfeiffer, N. Intraocular Pressure after Small Incision Cataract Surgery: Temporal Sclerocorneal versus Clear Corneal Incision. J. Cataract. Refract. Surg. 2001, 27, 421–425. [Google Scholar] [CrossRef] [PubMed]
- Simaroj, P.; Sinsawad, P.; Lekhanont, K. Effects of Intracameral Triamcinolone and Gentamicin Injections Following Cataract Surgery. J. Med. Assoc. Thail. = Chotmaihet Thangphaet 2011, 94, 819–825. [Google Scholar]
- Sipos, E.; Stifter, E.; Menapace, R. Patient Satisfaction and Postoperative Pain with Different Postoperative Therapy Regimens after Standardized Cataract Surgery: A Randomized Intraindividual Comparison. Int. Ophthalmol. 2011, 31, 453–460. [Google Scholar] [CrossRef]
- Solomon, K.D.; Stewart, W.C.; Hunt, H.H.; Stewart, J.A.; Cate, E.A. Intraoperative Intracameral Carbachol in Phacoemulsification and Posterior Chamber Lens Implantation. Am. J. Ophthalmol. 1998, 125, 36–43. [Google Scholar] [CrossRef]
- Stifter, E.; Luksch, A.; Menapace, R. Postoperative Course of Intraocular Pressure after Cataract Surgery with Combined Primary Posterior Capsulorhexis and Posterior Optic Buttonholing. J. Cataract. Refract. Surg. 2007, 33, 1585–1590. [Google Scholar] [CrossRef]
- Stifter, E.; Menapace, R.; Kriechbaum, K.; Luksch, A. Posterior Optic Buttonholing Prevents Intraocular Pressure Peaks after Cataract Surgery with Primary Posterior Capsulorhexis. Graefe’s Arch. Clin. Exp. Ophthalmol. = Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2010, 248, 1595–1600. [Google Scholar] [CrossRef]
- Studeny, P.; Hyndrak, M.; Kacerovsky, M.; Mojzis, P.; Sivekova, D.; Kuchynka, P. Safety of Hydroimplantation: A Foldable Intraocular Lens Implantation without the Use of an Ophthalmic Viscosurgical Device. Eur. J. Ophthalmol. 2014, 24, 850–856. [Google Scholar] [CrossRef]
- Waseem, M.; Rustam, N. Qamar ul Islam Intraocular Pressure after Phacoemulsification Using Hydroxypropyl Methylcellulose and Sodium Hyaluronate as Viscoelastics. J. Ayub Med. Coll. Abbottabad JAMC 2007, 19, 42–45. [Google Scholar] [PubMed]
- Wedrich, A.; Menapace, R. Intraocular Pressure Following Small-Incision Cataract Surgery and polyHEMA Posterior Chamber Lens Implantation. A Comparison between Acetylcholine and Carbachol. J. Cataract. Refract. Surg. 1992, 18, 500–505. [Google Scholar] [CrossRef] [PubMed]
- Wirtitsch, M.G.; Menapace, R.; Georgopoulos, M.; Rainer, G.; Buehl, W.; Heinzl, H. Intraocular Pressure Rise after Primary Posterior Continuous Curvilinear Capsulorhexis with a Fixed Dorzolamide-Timolol Combination: Randomized Safety Study with Intraindividual Comparison Using an Angulated and a Nonangulated Intraocular Lens. J. Cataract. Refract. Surg. 2007, 33, 1754–1759. [Google Scholar] [CrossRef]
- Wu, J.; Liang, G.; Zheng, Q.; He, F.; Liu, J.; Xu, W. Fusion Phaco Complex Phacoemulsification through a Coaxial 2.2 Mm Micro-Incision: A Clinical Study. Int. J. Clin. Exp. Med. 2018, 11, 9921–9930. [Google Scholar]
- Yaylali, V.; Ozbay, D.; Tatlipinar, S.; Yildirim, C.; Ozden, S. Efficacy and Safety of Rimexolone 1% versus Prednisolone Acetate 1% in the Control of Postoperative Inflammation Following Phacoemulsification Cataract Surgery. Int. Ophthalmol. 2004, 25, 65–68. [Google Scholar]
- Zebardast, N.; Zheng, C.; Jampel, H.D. Effect of a Schlemm’s Canal Microstent on Early Postoperative Intraocular Pressure after Cataract Surgery: An Analysis of the HORIZON Randomized Controlled Trial. Ophthalmology 2020, 127, 1303–1310. [Google Scholar] [CrossRef] [PubMed]
- Ziakas, N.G.; Boboridis, K.; Nakos, E.; Mikropoulos, D.; Margaritis, V.; Konstas, A.G.P. Does the Use of Trypan Blue during Phacoemulsification Affect the Intraocular Pressure? Can. J. Ophthalmol. 2009, 44, 293–296. [Google Scholar] [CrossRef]
- Messenio, D.; Ferroni, M.; Boschetti, F. Goldmann Tonometry and Corneal Biomechanics. Appl. Sci. 2021, 11, 4025. [Google Scholar] [CrossRef]
- Phulke, S.; Kaushik, S.; Kaur, S.; Pandav, S.S. Steroid-induced Glaucoma: An Avoidable Irreversible Blindness. J. Curr. Glaucoma Pract. 2017, 11, 67–72. [Google Scholar]
- Erichsen, J.H.; Forman, J.L.; Holm, L.M.; Kessel, L. Effect of anti-inflammatory regimen on early postoperative inflammation after cataract surgery. J. Cataract. Refract. Surg. 2021, 47, 323–330. [Google Scholar] [CrossRef] [PubMed]
- Kanjee, R.; Popovic, M.M.; Salimi, A.; Hutnik, C.M.L.; Ahmed, I.I.K.; Saheb, H. Prophylaxis against intraocular pressure spikes following uncomplicated phacoemulsification: A systematic-review and meta-analysis. Eye 2024, 38, 1518–1528. [Google Scholar] [CrossRef] [PubMed]
- Li, H.G.; Chen, Y.H.; Lin, F.; Li, S.Y.; Liu, Q.H.; Yin, C.G.; Chen, X.Y.; Zhang, X.J.; Qu, Y.; Hui, Y.N. Agreement of intraocular pressure measurement with Corvis ST, non-contact tonometer, and Goldmann applanation tonometer in children with ocular hypertension and related factors. Int. J. Ophthalmol. 2023, 16, 1601–1607. [Google Scholar] [CrossRef] [PubMed]
- De Bernardo, M.; Cione, F.; De Pascale, I.; Pagliarulo, S.; Rosa, N. Intraocular Pressure Measurements in Standing, Sitting, Prone, and Supine Positions. J. Pers. Med. 2024, 14, 826. [Google Scholar] [CrossRef]
- Birkeland, S.; Bismark, M.; Barry, M.J.; Möller, S. Is greater patient involvement associated with higher satisfaction? Experimental evidence from a vignette survey. BMJ Qual. Saf. 2022, 31, 86–93. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).